Beà Sílvia, Salaverria Itziar, Armengol Lluís, Pinyol Magda, Fernández Verónica, Hartmann Elena M, Jares Pedro, Amador Virginia, Hernández Luís, Navarro Alba, Ott German, Rosenwald Andreas, Estivill Xavier, Campo Elias
Hematopathology Unit, Department of Pathology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Blood. 2009 Mar 26;113(13):3059-69. doi: 10.1182/blood-2008-07-170183. Epub 2008 Nov 4.
Mantle cell lymphoma (MCL) is genetically characterized by the t(11;14)(q13;q32) translocation and a high number of secondary chromosomal alterations. However, only a limited number of target genes have been identified. We have studied 10 MCL cell lines and 28 primary tumors with a combination of a high-density single-nucleotide polymorphism array and gene expression profiling. We detected highly altered genomes in the majority of the samples with a high number of partial uniparental disomies (UPDs). The UPD at 17p was one of the most common, and it was associated with TP53 gene inactivation. Homozygous deletions targeted 4 known tumor suppressor genes (CDKN2C, BCL2L11, CDKN2A, and RB1) and 6 new genes (FAF1, MAP2, SP100, MOBKL2B, ZNF280A, and PRAME). Gene amplification coupled with overexpression was identified in 35 different regions. The most recurrent amplified regions were 11q13.3-q13.5, 13q31.3, and 18q21.33, which targeted CCND1, C13orf25, and BCL2, respectively. Interestingly, the breakpoints flanking all the genomic alterations, including UPDs, were significantly associated with genomic regions enriched in copy number variants and segmental duplications, suggesting that the recombination at these regions may play a role in the genomic instability of MCL. This integrative genomic analysis has revealed target genes that may be potentially relevant in MCL pathogenesis.
套细胞淋巴瘤(MCL)的遗传学特征是t(11;14)(q13;q32)易位以及大量继发染色体改变。然而,仅鉴定出有限数量的靶基因。我们结合高密度单核苷酸多态性阵列和基因表达谱研究了10个MCL细胞系和28例原发性肿瘤。我们在大多数样本中检测到高度改变的基因组,伴有大量部分单亲二体(UPD)。17p的UPD是最常见的之一,且与TP53基因失活相关。纯合缺失靶向4个已知的肿瘤抑制基因(CDKN2C、BCL2L11、CDKN2A和RB1)以及6个新基因(FAF1、MAP2、SP100、MOBKL2B、ZNF280A和PRAME)。在35个不同区域鉴定出基因扩增并伴有过表达。最常见的扩增区域是11q13.3 - q13.5、13q31.3和18q21.33,分别靶向CCND1、C13orf25和BCL2。有趣的是,所有基因组改变(包括UPD)两侧的断点与富含拷贝数变异和节段性重复的基因组区域显著相关,提示这些区域的重组可能在MCL的基因组不稳定性中起作用。这种综合基因组分析揭示了可能与MCL发病机制潜在相关的靶基因。